Comparison of irinotecan and oxaliplatin as the first-line therapies for metastatic colorectal cancer: a meta-analysis.

Sadayuki KawaiNozomi TakeshimaYu HayasakaAkifumi NotsuMutsumi YamazakiTakanori KawabataKentaro YamazakiKeita MoriHirofumi Yasui

Published in: BMC cancer (2021)

Although the safety profiles of IRI- and Ox-based regimens varied, their efficacy did not significantly differ. The combination of anti-VEGF antibody and IRI was associated with better PFS compared with anti-VEGF antibody and Ox. Both regimens could be used as the first-line treatments for mCRC with consideration of the patients' condition or toxicity profiles.

Keyphrases

metastatic colorectal cancer
end stage renal disease
vascular endothelial growth factor
endothelial cells
ejection fraction
chronic kidney disease
newly diagnosed
peritoneal dialysis
prognostic factors
patient reported outcomes
patient reported